Drug Delivery Technologies Market Forecast 2014-2024

Opportunities for Leading Companies

©noticeThis material is copyright by visiongain. It is against the law to reproduce any of this material without the prior written agreement of visiongain. You cannot photocopy, fax, download to database or duplicate in any other way any of the material contained in this report. Each purchase and single copy is for personal use only.

www.visiongain.com

Contents

1.1 Global Drug Delivery Technologies Market Overview

1.2 Global Drug Delivery Technologies Market Segmentation

1.3 Why You Should Read This Report

1.4 How This Report Delivers

1.5 Key Questions Answered by This Analytical Report

1.6 Who is This Report For?

1.7 Methodology

1.8 Frequently Asked Questions (FAQ)

1.9 Associated Reports

1.10 About Visiongain

2.1 Drug Delivery Technologies (DDT)

2.2 Drug Delivery Technologies - Types

2.2.1 Injection As a Route of Drug Delivery

2.2.2 Needle-free Transdermal Delivery

2.2.3 Oral Delivery Technologies

2.2.4 Inhalation or Spray

2.3 Sustained/Controlled Release Systems

2.4 Biopharmaceuticals

2.4.1 An introduction to the Biologic Drugs Market

2.4.2 Biologics: A Rising Drugs Market

2.4.3 Biotech Drugs with Associated Drug Delivery Technologies

2.4.4 Pegylated Interferons

2.4.5 Stiff Competition in Insulin Market Stimulating Investment in Drug Delivery

Technologies

2.4.6 The Main Challenges Facing Biological Drug Delivery

2.5 Market Definition

1. Report Overview

2. An Introduction to Drug Delivery

www.visiongain.com

Contents

3.1 Global Drug Delivery Technologies: Market Overview

3.1.1 Drug Delivery Technologies: A Growing Market

3.2 The Global Drug Delivery Technologies Market in 2013

3.2.1 Global Drug Delivery Technologies: Market Forecast 2014-2024

3.2.2 Changing Market Shares by Sector 2014-2024

3.3 Oral Drug Delivery Technologies Market 2014-2024

3.3.1 Oral Drug Delivery Technologies: Market Forecast 2014-2024

3.4 Inhalation Drug Delivery Technologies Market 2014-2024

3.4.1 Inhalation Drug Delivery Technologies: Market Forecast 2014-2024

3.5 Injectable/Implants Drug Delivery Technologies Market 2014-2024

3.5.1 Injectable/Implants Drug Delivery Technologies: Market Forecast 2014-2024

3.6 Transdermal Drug Delivery Technologies Market 2014-2024

3.6.1 Transdermal Drug Delivery Technologies: Market Forecast 2014-2024

3.7 Ocular Drug Delivery Technologies Market 2014-2024

3.7.1 Ocular Drug Delivery Technologies: Market Forecast 2014-2024

3.8 Nasal Drug Delivery Technologies Market 2014-2024

3.8.1 Nasal Drug Delivery Technologies: Market Forecast 2014-2024

4.1 The Drug Delivery Technologies Market by Regional Revenue

4.1.1 The Global Distribution of Drug Delivery Technologies in 2013

4.2 Leading National Markets: Forecast, 2014-2024

4.2.1 Changing Market Shares by Region, 2014-2024

4.3 Regional Drug Delivery Technologies Markets: Analysis and Forecasts, 2014-2024

4.3.1 United States: The Largest Market for Drug Delivery Technologies

4.3.2 The EU5 Markets:

4.3.2.1 EU5: Changing Market Shares by Country, 2014-2024

4.3.2.2 Germany: Fiscal Austerity Programs and Spending Cuts

4. Leading National Markets 2014-2024

3. The Global Drug Delivery Technologies Market, 2014-2024

www.visiongain.com

Contents

4.3.2.3 France: Strong Drug Discovery Landscape

4.3.2.4 UK: An Increasingly Service-Oriented Market

4.3.2.5 Spain: Recovering Economy to Stimulate Healthcare Investment

4.3.2.6 Italy: Changing Reimbursement Culture Will Aid Market Growth

4.3.3 Japan: Aging Population Stimulating Drug Demand

4.3.4 China: Intensive Talent Resource and Relative Low Cost

4.3.5 India: A Hotbed For Drug Delivery Technology Manufacturing and Outsourcing

4.3.6 Brazil: Government Subsidies Boosting Drug Production

4.3.7 Russia: Availability of Custom Libraries for Drug Molecules Will Catalyse Growth

4.3.8 South Korea: Acquisition of Promising Overseas Companies Will Aid Market Growth

4.3.9 Mexico: Government Initiatives and Regulatory Changes Boosting Market Growth

4.3.10 Rest of the World

5.1 Therapeutic Areas Offering Growth Opportunities

5.2 Biologics: A Future Driver for Growth in Drug Delivery Technologies

5.2.1 Leading Classes of Biological Drugs, 2013

5.3 Monoclonal Antibodies: Largest Sector in Biologics

5.3.1 Monoclonal Antibodies: Prospects, Forecast, and Implications for Drug Delivery

Technologies

5.4 Human Insulins

5.4.1 Insulins: Prospects, Forecast, and Implications for Drug Delivery Technologies

5.4.2 Exubera: An Alternative Delivery Method for Biological Drugs

5.4.2.1 The First Inhaled Insulin

5.4.2.2 A History of Exubera: Development and Post-Marketing

5.4.3 Generex and MannKind Developing Next-Generation Oral Insulins

5.4.4 Challenges Facing Oral-lyn and Afrezza

5.5 Interferons

5.5.1 Interferons: Prospects, Forecast, and Implications for Drug Delivery Technologies

5.6 Erythropoietin Products

5. Leading Drug Classes Offering Growth for Drug Delivery

www.visiongain.com

Contents

5.6.1 Erythropoietins: Prospects, Forecast, and Implications for Drug Delivery

Technologies

5.7 Granular-Colony Stimulating Factors (G-CSF)

5.7.1 Granular-Colony Stimulating Factors (G-CSF): Prospects, Forecast, and Implications

for Drug Delivery Technologies

5.8 Recombinant Coagulation Factors

5.8.1 Recombinant Coagulation Factors: Prospects, Forecast, and Implications for Drug

Delivery Technologies

5.9 Other Therapeutic Proteins

5.9.1 Other therapeutic Proteins: Prospects, Forecast, and Implications for Drug Delivery

Technologies

5.10 The Biosimilars Market in 2013

5.10.1 Biosimilars: Prospects, Forecast, and Implications for Drug Delivery Technologies

5.11 The Vaccines Market in 2013

5.11.1 Vaccines: Market Forecast 2014-2024

5.12 The Role of Biologics in the Drug Delivery Technologies Market

6.1 Drug Delivery Technologies: A Fragmented Market

6.2 Leading Companies in Inhaled Drug Delivery Technologies

6.2.1 3M: A Global Health Information Systems Provider

6.2.1.1 3M Healthcare Revenue Analysis, 2013

6.2.1.2 3M’s Drug Delivery Technologies

6.2.1.2.1 Protein and Peptide Delivery

6.2.1.2.2 Excipient Technology for CFC-Free Inhalers

6.2.1.2.3 Actuator Technology for Metered Dose Inhalers

6.2.1.2.4 Particle Engineering Technology

6.2.2 Aradigm Corporation

6.2.2.1 AERx Drug Delivery System

6. Leading Companies in the Drug Delivery Technologies Market, 2014

www.visiongain.com

Contents

6.2.2.2 Aradigm’s Partnerships

6.2.2.3 Aradigm’s Pipeline Products

6.2.3 Vectura Group

6.2.3.1 Vectura’s Technologies and Products

6.2.3.2 Vectura’s Development Pipeline

6.3 Leading Companies in Oral Drug Delivery Technologies

6.3.1 Applied Pharma Research (APR)

6.3.1.1 APR’s Technology and Product Offerings

6.3.2 Catalent Pharma

6.3.2.1 Catalent’s Drug Delivery Technologies

6.3.2.2 Catalent Revenue Analysis, 2009-2013

6.3.2.3 Catalent’s Recent Activities

6.3.3 Emisphere Technologies

6.3.3.1 Emisphere’s Eligen Technology

6.3.3.2 Emisphere Revenue Analysis, 2010-2013

6.3.3.3 Emisphere: Pipeline Products

6.3.4 Ethypharm

6.3.4.1 Ethypharm’s Drug Delivery Technologies

6.3.4.2 Ethypharm’s Currently Marketed Products

6.3.5 Glycologic

6.3.5.1 Glycologic’s Drug Delivery Technologies

6.3.5.2 Glycologic’s Pipeline Developments

6.4 Leading Companies in Injectable Drug Delivery Technologies

6.4.1 Alkermes

6.4.1.1 Alkerme’s Drug Delivery Technologies

6.4.1.2 Alkermes Revenue Analysis, 2009-2013

6.4.1.3 Alkerme’s Product Pipeline

6.4.2 Pacira Pharmaceuticals

6.4.2.1 Pacira’s Injectable Sustained–Release Technologies

6.4.2.2 Pacira Pharmaceuticals: Revenue Analysis, 2009-2013

6.5 Leading Companies in Transdermal Drug Delivery Technologies

www.visiongain.com

Contents

6.5.1 Nanopass Technologies

6.5.1.1 Nanopass Drug Delivery Products

6.5.1.1.1 Anti-aging Microdermabrasion

6.5.1.1.2 Microjet Needle

6.5.2 Noven Pharmaceuticals

6.5.2.1 Noven Pharmaceuticals’ Transdermal Products

6.5.2.2 Noven’s Development Pipeline

6.6 Leading Companies for Transmucosal Drug Delivery

6.6.1 CIMA Labs

6.6.1.1 CIMA’s Transmucosal Drug Delivery Technologies

6.6.1.2 The OTS System

6.6.1.3 OraVescent Technology

6.6.2 Columbia Laboratories

6.6.2.1 Columbia Labs’ Bioadhesive Delivery Technology

6.6.2.2 Columbia Labs’ Products

6.6.2.3 Columbia Labs Revenue Analysis, 2009-2013

6.6.3 Generex Biotechnology Corporation

6.6.3.1 Generex’s Products

6.6.3.2 Generex: Revenue Analysis, 2011-2013

6.7 Leading Implantable Drug Delivery Technology Companies

6.7.1 pSivida Corporation

6.7.1.1 pSivida’s Drug Delivery Technologies

6.7.1.1.1 Durasert Technology

6.7.1.1.2 Tethadur Technology

6.7.2 pSivida Products

7.1 SWOT Analysis of the Drug Delivery Technologies Market, 2014-2024

7.2 Strengths

7. Qualitative Analysis of the Drug Delivery Technologies Market 2014-2024

www.visiongain.com

Contents

7.2.1 Biosimilars: Legislations Encouraging Innovation

7.2.2 Patent Expiries and the Resulting Increase in Competition Will Favour Drug Delivery

Technologies

7.2.3 Monoclonal Antibodies Will Drive Delivery Technologies

7.2.4 PEGylation Assisting Growth

7.3 Weaknesses

7.3.1 Risk-Conscious Regulatory Bodies Will Make Approval Difficult

7.4 Opportunities

7.4.1 Nanotechnology: Innovations That Will Benefit Drug Delivery

7.4.2 Possible New Delivery Methods for Insulin

7.4.3 Availability of Cost effective Solutions Will Stimulate Uptake of Drug Delivery

Technologies

7.5 Threats

7.5.1 The Conservative Mindset of Drug Developers May Hinder Innovation in Drug

Delivery

7.5.2 The Current Limit on Feasible Route of Administration for Biotech Drugs May Limit

Drug Delivery Growth

7.5.3 Lifecycle Management via Protein Engineering Blurs Drug Delivery Lines

8.1 Interview with Dr Sven Frokjaer, Dean and Professor of Pharmaceutical Sciences, University of

Copenhagen, Denmark

8.1.1 On the Current State of Drug Delivery Technologies

8.1.2 The ‘Magic Bullet’ – A Challenge for Innovation

8.1.3 Self-Assembling Protein Systems and the Use of Nanostructures for Drug Targeting

8.1.4 Technological Developments in Drug Development – Quantum Dots, Silicon

Structures, and Polymeric Materials

8.1.5 On Future Challenges and Opportunities

8.2 Interview with Dr Claus Michael Lehr, Head of Department, Drug Delivery at the Helmholtz

Institute for Pharmaceutical Research Saarland (HIPS)

8. Expert Opinions

www.visiongain.com

Contents

8.2.1 The Need for Novel Delivery Mechanisms Driving Growth

8.2.2 Therapeutic Areas That Are Propelling Drug Delivery Technologies

8.2.3 Drug Delivery Barriers and the Need for Targeting

8.2.4 Advancements in Drug Delivery in the Coming Years

8.2.5 Future Challenges for Drug Delivery Technologies

8.2.6 Future Opportunities for Drug Delivery Technologies

9.1 Market Overview

9.2 Commercial Drivers for Drug Delivery Technology

9.3 Transdermal Drug Delivery Technologies Set For High Growth

9.4 Biologics Will Drive Market Growth

9.5 Leading Companies in the Drug Delivery Technologies Market

9.6 Growth Concentrated in Developed Markets and in the Innovative Markets of South America

and South Asia

9.7 Future Prospects for Drug Delivery Technologies

9. Conclusion

Page 85

www.visiongain.com

Drug Delivery Technologies Market Forecast 2014-2024: Opportunities for Leading Companies

was estimated at $6.2bn in 2013 (Table 4.13). This represents 22.4% of the total EU5 market in

2013.

Table 4.13 The French Drug Delivery Technologies Market Forecast: Revenue ($bn),

Market Rank, Market Share (%) and CAGR (%), 2013-2024

2013 2018 2024Market Size ($bn) 6.2 9.7 14.8Global Market Ranking 4th 5th 6thEU5 Market Share (%) 22.4 23.0 22.8

2013-2024 CAGR (%)Market Outlook

2013-20248.2

Positive

In recent years, as a result of the global financial crisis, there have been a number of research

project cancellations in France. However, as the economy recovers and these research projects

are resurrected, visiongain notes that these drug development projects will explore various delivery

technologies for administering the therapies. The introduction of innovative new drugs resulting

from these development projects will help to boost the French drug delivery technologies market.

Visiongain concludes that the French drug delivery technologies market will grow from $6.2bn in

2013 to $9.7bn in 2018, rising with a CAGR of 9.4% between 2013 and 2018 (Table 4.14). The

French market will then further rise to $14.8bn in 2024 (Figure 4.17), at a CAGR of 7.3% between

2018 and 2024.

Table 4.14 The French Drug Delivery Technologies Market: Forecast ($bn, AGR%,

CAGR%), 2013-2024

2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

French Market ($bn) 6.2 6.8 7.3 8.1 8.9 9.7 10.6 11.4 12.3 13.1 13.9 14.8

AGR (%) 9 9 10 10 9 9 8 8 7 6 6CAGR (%) 2013-18CAGR (%) 2013-24

9.4 2018-24 7.38.2

Source: Visiongain 2014

Source: Visiongain 2014

Page 122

www.visiongain.com

Drug Delivery Technologies Market Forecast 2014-2024: Opportunities for Leading Companies

chemotherapy has been suggested as a plausible measure of the savings G-CSF products make

possible. The products can be self-administered at home.

5.7.1 Granular-Colony Stimulating Factors (G-CSF): Prospects, Forecast,

and Implications for Drug Delivery Technologies Although governmental cost-cutting measures have slowed the growth of the G-CSF market in the

EU and US, other G-CSF and GM-CSF products are coming onto the market. Some of these are

biosimilars, with G-CSF representing one of the major targets for biosimilar competition. Teva, CT

Arzneimittel, Hospira and Sandoz have all pioneered biosimilar versions of Amgen’s originals.

Despite this, visiongain believes the branded market for G-CSF products will also continue to grow,

reaching $17.4bn sales in 2024, with a CAGR of 7.9% from 2018 to 2024 (Tables 5.8 and Figure

5.5).

Figure 5.5 Granular-Colony Stimulating Factors (G-CSF): Global Sales Forecast ($bn,

AGR%), 2013-2024

0

2

4

6

8

10

12

14

16

0.0

2.0

4.0

6.0

8.0

10.0

12.0

14.0

16.0

18.0

20.0

2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

AGR

(%)

Mar

ket S

ize

($bn

)

Year

Sales ($bn) AGR (%)

Source: Visiongain 2014

Page 155

www.visiongain.com

Drug Delivery Technologies Market Forecast 2014-2024: Opportunities for Leading Companies

Figure 6.5 Alkermes: Historical Revenue ($m), 2009-2013

6.4.1.3 Alkerme’s Product Pipeline Alkermes currently have a number of products under development, some of which are being

developed in partnership with companies such as Eli Lilly and Amylin. Some of these products are

described in Table 6.10.

Table 6.10 Alkerme’s Product Pipeline, 2014

Candidate Therapeutic Category Phase

ZOHYDRO Pain Approved

ALKS 9070 Schizophrenia III

INVEGA SUSTENNA 3-month Schizophrenia III

Exenatide Once Monthly Type II Diabetes III

Meloxicam IV Pain II

ALKS 5461 Major Depressive Disorder III

ALKS 5461 Cocaine Addiction III

ALKS 3831 Major Depressive Disorder III

MMF Prodrug ALKS 8700 Multiple Sclerosis Preclinical

ALKS 7106 Pain Preclinical

RDB 1419 Cancer Preclinical

326.8

178.2 186.6

390.0

575.5

0.0

100.0

200.0

300.0

400.0

500.0

600.0

700.0

2009 2010 2011 2012 2013

Rev

enue

($m

)

Year

Source: Alkermes 2014, Visiongain 2014

Source: Alkermes 2014, Visiongain 2014